title: Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy.
abstract: Mucopolysaccharidosis type I (MPS-I or Hurler syndrome) is an inherited deficiency of the lysosomal glycosaminoglycan (GAG)-degrading enzyme alpha-l-iduronidase (IDUA) in which GAG accumulation causes progressive multi-system dysfunction and death. Early allogeneic hematopoietic stem cell transplantation (HSCT) ameliorates clinical features and extends life but is not available to all patients, and inadequately corrects its most devastating features including mental retardation and skeletal deformities. To test novel therapies, we characterized an immunodeficient MPS-I mouse model less likely to develop immune reactions to transplanted human or gene-corrected cells or secreted IDUA. In the liver, spleen, heart, lung, kidney and brain of NOD/SCID/MPS-I mice IDUA was undetectable, and reduced to half in heterozygotes. MPS-I mice developed marked GAG accumulation (3-38-fold) in these organs. Neuropathological examination showed GM(3) ganglioside accumulation in the striatum, cerebral peduncles, cerebellum and ventral brainstem of MPS-I mice. Urinary GAG excretion (6.5-fold higher in MPS-I mice) provided a non-invasive and reliable method suitable for serially following the biochemical efficacy of therapeutic interventions. We identified and validated using rigorous biostatistical methods, a highly reproducible method for evaluating sensorimotor function and motor skills development. This Rotarod test revealed marked abnormalities in sensorimotor integration involving the cerebellum, striatum, proprioceptive pathways, motor cortex, and in acquisition of motor coordination. NOD/SCID/MPS-I mice exhibit many of the clinical, skeletal, pathological and behavioral abnormalities of human MPS-I, and provide an extremely suitable animal model for assessing the systemic and neurological effects of human stem cell transplantation and gene therapeutic approaches, using the above techniques to measure efficacy.
authors.affiliation: Department of Neurosurgery, University of Minnesota, Minneapolis, MN, USA.
authors.forename: Mayra F
authors.initials: MF
authors.lastname: Garcia-Rivera
authors.forename: Leah E
authors.initials: LE
authors.lastname: Colvin-Wanshura
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Nelson
authors.forename: Zhenhong
authors.initials: Z
authors.lastname: Nan
authors.forename: Shaukat A
authors.initials: SA
authors.lastname: Khan
authors.forename: Tyson B
authors.initials: TB
authors.lastname: Rogers
authors.forename: Indrani
authors.initials: I
authors.lastname: Maitra
authors.forename: Walter C
authors.initials: WC
authors.lastname: Low
authors.forename: Pankaj
authors.initials: P
authors.lastname: Gupta
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D015316:Genetic Therapy; D006025:Glycosaminoglycans / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008817:Mice, Mutant Strains; D009083:Mucopolysaccharidoses / Q000473:pathology* / Q000503:physiopathology* / Q000628:therapy*; D033581:Stem Cell Transplantation
chemical_list: D006025:Glycosaminoglycans